Clinical trials: First Relapse
Lung Cancer
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.
- Trial name
- CheckMate331 (NCT02481830)
- Testing
- Nivolumab, Topotecan, Amrubicin
- Where
- 151 sites in United States, Australia and 23 more
- Volunteers
- 569 people
- Sponsor
- Bristol-Myers Squibb
Breast Neoplasms
To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent
To determine the Objective Response Rate of 4 cycles of docetaxel + anthracycline (epirubicin or doxorubicine) followed by 4 cycles of docetaxel single agent.
- Trial name
- NCT00620100
- Testing
- Docetaxel
- Where
- 2 sites in Austria, Poland
- Volunteers
- 2 people
- Sponsor
- Sanofi
Advanced Tumor, Lymphoma
To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors
Patients with advanced tumors diagnosed histologically or cytologically at the study center who were refractory to standard therapy or had relapsed received XNW5004 tablets
- Trial name
- NCT06558513
- Testing
- XNW5004 tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Evopoint Biosciences Inc.
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
The goal of this national, multicenter single arm phase II clinical trial is to study the efficacy, safety and tolerability of the administration of Trastuzumab Deruxtecan (T-DXd) in HER2-positive locally advanced or metastatic…
- Trial name
- TRANSCENDER (NCT05744375)
- Testing
- Trastuzumab deruxtecan
- Where
- 19 sites in Spain
- Volunteers
- 2 people
- Sponsor
- Spanish Breast Cancer Research Group
Leukemia, Lymphoma
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003395
- Testing
- arsenic trioxide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC
Lung cancer is the leading cause of cancer death in Korea as well as in other countries. About 80% of lung cancer is non-small cell lung cancer(NSCLC).
- Trial name
- BELOXAN (NCT01243775)
- Testing
- Belotaxel, Belloxa
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Chonnam National University Hospital
Cancer, Relapsed Cancer
myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports
The purpose of this study is to determine the benefit of Cellworks Singula™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications who have already received…
- Conditions
- Cancer, Relapsed Cancer, Refractory Cancer
- Trial name
- myCare-102 (NCT05693831)
- Testing
- Cellworks Report
- Where
- United States
- Volunteers
- 730 people
- Sponsor
- Cellworks Group Inc.
Leukemia, Acute Myeloid, Myelodysplastic Syndromes
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment.
- Conditions
- Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell
- Trial name
- NCT05362773
- Testing
- MGD024
- Where
- 7 sites in United States
- Volunteers
- 130 people
- Sponsor
- MacroGenics
Acute Myeloid Leukemia, Acute Leukemia
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
New conditioning regimens are still needed to maximize efficacy and limit treatment-related deaths of allogeneic transplantation for advanced hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma
- Trial name
- NCT01499147
- Testing
- fludarabine/busulfan, fludarabine/ melphalan, ATG
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Illinois Chicago
Bone Sarcoma, Osteosarcoma
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Randomized, non-comparative, multicentre exploratory phase II study. Two arms concerning patients with bone sarcoma after the first line therapy: in the first arm, patients will be treated with Regorafenib for a maximum of 12…
- Conditions
- Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma
- Trial name
- REGOSTA (NCT04055220)
- Testing
- Treatment by Regorafenib, Surveillance
- Where
- 16 sites in France
- Volunteers
- 168 people
- Sponsor
- Centre Leon Berard
Acute Lymphoblastic Leukemia, Infections
Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO
The goal of this observational study is to learn about infectious complications in patients affected by B-cell acute lymphoblastic leukemia treated with inotuzumab-ozogamicin (INO).
- Conditions
- Acute Lymphoblastic Leukemia, Infections, Bacterial Infections, Viral Infection
- Trial name
- INO-FIRST (NCT06025682)
- Where
- Italy
- Volunteers
- 158 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia
Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients
The objective of this protocol is to collect leukemia cell specimens from adults (18 years of age) diagnosed with acute leukemia at time of initial diagnosis and, if applicable, at time of first relapse.
- Trial name
- NCT00631059
- Testing
- Hem(A)+ Technology
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, Irvine
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Patients are being asked to participate in this study because they will be receiving a stem cell transplant as treatment for their disease.
- Conditions
- Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
- Trial name
- CASPALLO (NCT00710892)
- Testing
- Allodepleted T Cells
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Baylor College of Medicine
Hematologic Malignancies
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second…
- Trial name
- NCT06807606
- Testing
- Drugs Cyclophosphamide, Fludarabine, Thiotepa
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Estrogen can stimulate the growth of cancer cells. Letrozole may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00014638
- Testing
- letrozole
- Where
- 20 sites in United States
- Sponsor
- Novartis
Acute Myeloid Leukemia
CNDO-109-AANK for AML in First Complete Remission (CR1)
This is a multi-center, open-label, non-controlled, non-randomized dose-escalating Phase 1 clinical study designed to examine the safety of infusing escalating doses of CNDO-109-Activated Allogeneic Natural Killer Cells-(from a…
- Trial name
- NCT01520558
- Testing
- CNDO-109-AANK Cells
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Coronado Biosciences, Inc.
Steroid-Sensitive Nephrotic Syndrome
Comparison of Relapse Rate After 12 Weeks Verses 20 Weeks Steroid Therapy for the Management of First Episode of Steroid Sensitive Nephrotic Syndrome
All children from 1 to 8 years of age, diagnose with nephrotic syndrome for the first time will be divided into two groups. One group will be given steroids for 12 weeks and other group will receive steroid for 20 weeks.
- Trial name
- NCT04713410
- Testing
- Prednisolone
- Where
- Pakistan
- Volunteers
- 68 people
- Sponsor
- Shaheed Zulfiqar Ali Bhutto Medical University
Solid Tumor, Breast Cancer
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant…
- Conditions
- Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT05989724
- Testing
- SON-DP
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Qurgen Inc.
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Trial name
- NCT01053494
- Testing
- massage therapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Fever, Sweats, and Hot Flashes, Infection
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma
- Trial name
- NCT00020865
- Testing
- cefepime hydrochloride, levofloxacin
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center